Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Immunovant (Nasdaq: IMVT) has appointed Dr. Rita Jain as Chief Medical Officer, bringing over 20 years of drug development expertise. Dr. Jain's extensive experience in clinical trials, particularly in immunology and inflammation, positions her to lead multiple Phase 3 programs for IMVT-1401. Additionally, due to COVID-19-related site closures, results for key trials of IMVT-1401 are now delayed, with expectations for updates in Q2 and Q3 of 2021. The company remains optimistic about IMVT-1401's potential in various therapeutic areas.
Immunovant reported its fiscal second quarter results ending September 30, 2020, with approximately $444 million in cash and a net loss of $20.8 million ($0.25 per share). R&D expenses rose to $12.0 million primarily due to increased clinical trial costs. The company appointed Michael Elliott as Chief Scientific Officer and reported positive results from its IMVT-1401 trial for Myasthenia Gravis. Additionally, they raised $188 million through a public equity offering. Upcoming results for ongoing trials are anticipated in 2021.
Immunovant, Inc. (Nasdaq: IMVT) has successfully closed its underwritten public offering of 6,060,606 shares of common stock at $33.00 per share, raising approximately $200.0 million in gross proceeds. This includes the full exercise of an underwriters’ option for an additional 790,513 shares. The offering was managed by SVB Leerink, Guggenheim Securities, and Chardan, with LifeSci Capital and Baird as co-lead managers. The registration statements for these securities became effective on September 1, 2020.
Immunovant, Inc. (Nasdaq: IMVT) appointed Michael Elliott, MBBS, PhD as Chief Scientific Officer. He brings over 23 years of R&D experience, including 17 years at Johnson & Johnson, where he led the development of innovative immunology products. Elliott will oversee the advancement of IMVT-1401, a novel antibody treatment for autoimmune diseases. The company is currently in a productive phase with three programs in Phase 2. CEO Pete Salzmann highlighted Elliott's expertise in identifying best-in-class opportunities, vital for the company’s growth.
Immunovant, Inc. (Nasdaq: IMVT) reported its financial results for the fiscal first quarter ending June 30, 2020, revealing a net loss of $26.7 million, up from $20.1 million a year prior. Cash reserves stood at approximately $280.3 million. Research and development (R&D) expenses decreased by $1.6 million to $16.9 million; however, adjusting for a one-time milestone payment in the prior year, R&D expenses actually increased by $8.5 million due to higher clinical trial costs. General and administrative (G&A) expenses surged by $8.1 million to $9.7 million, attributed to rising personnel costs and legal fees.
Immunovant, Inc. (Nasdaq: IMVT) announced that warrant holders have until June 15, 2020, to exercise 11.5 million outstanding warrants, potentially raising $66.125 million at a price of $11.50 per share. The warrants are subject to mandatory redemption if its stock price stays above $16.50 for 20 trading days. Additionally, Immunovant is triggering the issuance of 10 million shares to former shareholders after meeting specific price conditions. The company remains focused on developing treatments for autoimmune diseases.